newself tirzepatide F.D.A. Approves New Obesity Drug That Will Compete With Wegovy Tirzepatide cuts risk of diabetes

Authorization for pediatric patients aged 12 years and older followed in 2022

Our physician-led team provides evidence-based menopause treatment that addresses the full spectrum of changes, from hot flashes and night sweats to mood shifts and vaginal health concerns

Fluoxetine does not produce any of these responses in patients

Studies directly characterizing the effects of treatment with tirzepatide in patients with T2D and/or obesity and COVID-19 or long COVID have not been published yet

Sustainable Results: Our treatments help patients lose weight and maintain their success long-term

You need a concentration that works at both your starting dose and your eventual maintenance dose